CDT Equity Inc. (CDT) stock
CDTNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CDTTW
$0.44−0.07 (-13.10%)
Close on Nov 12, 2026Market cap $348.65KP/E –Yield –
CDT Equity r&d expenses
Research and development expenses are spending on new products and technology.
CDT Equity's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.36M, down 44.0% year over year. For fiscal 2025 it was $5.05M, up 49.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.05M | +49.6% |
| FY2024 | Dec 31, 2024 | $3.38M | +3653.3% |
| FY2023 | Dec 31, 2023 | $90.00K | +143.2% |
| FY2022 | Dec 31, 2022 | $37.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $302.00K | -83.8% |
| Q1 FY2026 | Mar 31, 2026 | $778.00K | -15.1% |
| Q4 FY2025 | Dec 31, 2025 | $746.00K | +465.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.53M | -50.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.86M | +7340.0% |
| Q1 FY2025 | Mar 31, 2025 | $916.00K | +615.6% |
| Q4 FY2024 | Dec 31, 2024 | $132.00K | +247.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.09M | – |
| Q2 FY2024 | Jun 30, 2024 | $25.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $128.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $38.00K | – |
See a number that looks wrong?